These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8735793)

  • 1. Family issues in continuous infusion therapy with factor VIII.
    Manco-Johnson MJ
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S21-5. PubMed ID: 8735793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and indications for continuous infusion of antihemophilic factor (factor VIII).
    Goldsmith JC
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S3-6. PubMed ID: 8735789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous infusion of factor VIII for surgery and major bleeding.
    Hay CR; Doughty HI; Savidge GF
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S15-9. PubMed ID: 8735792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor VIII pharmacokinetics: intermittent infusion versus continuous infusion.
    Morfini M; Messori A; Longo G
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S11-4. PubMed ID: 8735791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis and continuous infusion for hemophilia: can we afford it?
    Aledort LM; Bohn RL
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S35-7. PubMed ID: 8735795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis in haemophilic children.
    Liesner RJ
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S7-10. PubMed ID: 9351529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro factor VIII recovery during the delivery of ultrapure factor VIII concentrate by continuous infusion.
    DiMichele DM; Lasak ME; Miller CH
    Am J Hematol; 1996 Feb; 51(2):99-103. PubMed ID: 8579073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal purified F VIII for continuous infusion: stability, microbiological safety and clinical experience.
    Schulman S; Varon D; Keller N; Gitel S; Martinowitz U
    Thromb Haemost; 1994 Sep; 72(3):403-7. PubMed ID: 7855792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Massive factor-VIII infusion in Haemophiliac with factor-VIII inhibitor, high responder. 1977.
    Brackmann HH; Gormsen J
    Haemophilia; 2010 May; 16(102):2-3. PubMed ID: 20536980
    [No Abstract]   [Full Text] [Related]  

  • 10. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between factor VIII replacement therapy and joint damage in severe haemophilia.
    Lowe GD
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S3-5. PubMed ID: 9351528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Family pediatrics: report of the Task Force on the Family.
    Schor EL;
    Pediatrics; 2003 Jun; 111(6 Pt 2):1541-71. PubMed ID: 12777595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic infusion regimens in the management of hemophilia.
    Ljung RC
    Thromb Haemost; 1999 Aug; 82(2):525-30. PubMed ID: 10605746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in care of children with hemophilia.
    Manco-Johnson MJ; Riske B; Kasper CK
    Semin Thromb Hemost; 2003 Dec; 29(6):585-94. PubMed ID: 14719175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular access in hemophilia.
    Powell TW; Blumoff RL; Mandel SR
    Am Surg; 1981 Sep; 47(9):408-9. PubMed ID: 6792959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and assessment of clinical trials on continuous infusion.
    Schulman S; Martinowitz U
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S7-9. PubMed ID: 8735790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant factor VIII in hemophilia A: the Canadian experience.
    Blanchette VS
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of hemophilia A with actor VIII concentrate in urological operations and injuries of the urinary tract].
    Brühl P; Weibbach L; Brackmann HH
    MMW Munch Med Wochenschr; 1975 Mar; 117(10):401-4. PubMed ID: 804604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.